Increasing epidemic diseases fuel excipients market
The increase in the outbreak of pandemic or epidemic diseases across the globe is the primary factor for boosting the growth of the pharmaceutical excipients market.
The problems associated with instability, poor solubility, and absorption of active pharmaceutical ingredients are driving the demand for excipients. The development of nanotechnology for the administration of drugs is further boosting the growth of the market.
According to the current analysis of Reports and Data, the global pharmaceutical excipients market which was valued at US$ 6.53 billion in 2019, is expected to reach US$ 10.15 billion by the year 2027, at a CAGR of 5.7 per cent.
In 2015, the amount of manufacturing of final products of drugs in Japan accounted for 6,820.4 billion yen, the amount of import was 4,022 billion yen. Increasing outbreak of life threatening diseases and increasing incidences of resistance over traditional treatment plan resulting in increasing number of final production are expected to boost the market growth.
North America has obtained remarkable growth in the market due to the awareness among the consumers for better healthcare, government initiatives for research and development of new drugs, clinical trials, and due to better facilities for healthcare in the region. However, the high cost of drug development is the primary restraint to market growth.
The sudden outbreak of Covid-19 has reported significant growth in the pharmaceutical excipients market. According to the recent epidemiological data the fight against Covid is expected to continue furthermore for some considerable time, especially in Europe.
Excipients are the products that do not show any activity of the drug but facilitates the drug delivery process.
Pharmaceutical companies are engaged in developing the appropriate and desired treatment plan or medicines. Increasing production of final products in the industry has gained huge demand of excipients required for the formulation. However, it might impact negatively to emerging nations in Asia such as China and India, due to the increased restrictions towards international trade i.e., export or import.
In such circumstances, companies especially in US and Europe have shifted towards manufacturer from the same state or backward expansion strategies, i.e., companies are owning their own excipients manufacturing plants. For instance, ReForm Biologics, a pharmaceutical technology company and MilliporeSigma have entered an agreement and collaboration to commercialize proprietary ReForm excipients used in biotherapeutic formulations.
Certain excipients have been established high acceptance for manufacturing drug for Covid treatment for example, hydroxypropyl beta-cyclodextrins (HPßCD) it acts as functional excipient. Certain bodies are also playing vital role in market impact of Covid outbreak. EXCiPACT updated position paper on Covid. EXCiPACT asbl is a non-profit organisation that require excipient users to qualify their suppliers based on GMP/GDP audits. It regulates such an independent, high quality, third party Certification Scheme available to pharmaceutical excipient manufacturers and distributors worldwide.
Evonik in the year 2017 had launched a new sterile, and ultra-low-metal content bioresorbable polymers known as Resomer Zero it is an ultra-low tin content PLGA poly (lactic-co-glycolic acid) excipient and is the first sterile controlled release (PLGA) excipient in the market. It was designed for the controlled-release parenteral drug formulation.
Croda International, in the year 2018 had launched Moonshine Effect Pigments, it is a range of borosilicate-based effect pigments, it is specially designed for personal care products, the quality borosilicate substrate produces the effect exceptional vibrancy, intensity, and color transmission for eye-catching results in cosmetic formulations.
JRS Pharma had received an EXCiPACT Certificate from DQS for the production of Microcrystalline Cellulose and Silicified Microcrystalline Cellulose and for Good Distribution Practice for the central logistic warehouse. The certificate justifies that the Micro cellulose is manufactured and distributed according to the EXCiPACT Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) Certification Standard. The certificate is beneficial for the drug manufacturers to reduce their efforts and costs for performing quality control.
Oral formulations in the formulations segment have obtained the largest share due to the rise in demand for formulations like tablets, capsules, and oral solutions and suspensions. It is likely to grow with a CAGR of 5.9 per cent in the forecast period.
Ashland Global Holdings (US), BASF SE (Germany), DuPont (US), Roquette Feres (France), Evonik Industries AG (Germany), Associated British Foods (UK), Archer Daniels Midland Company (US), Lubrizol Corporation (US), Croda International (UK). Innophous Holdings (US), Kerry Group (Ireland), WACKER Chemie AG (Germany), Colorcon (US), DFE Pharma (Germany), JRS Pharma (Germany), and Air Liquide (France) are the key players in the pharmaceutical excipients market.
